Clinical significance of promoter hypermethylation of RASSF1A, RARβ2, BRCA1 and HOXA5 in breast cancers of Indian patients
Authors:
- Chandra Prakash PrasadChandra Prakash Prasad
- Jatinder KaurJKJatinder Kaur
- Ranju RalhanRRRanju Ralhan
- 1 June 2008
- journal article
- Published by Elsevier in Life Sciences
- Vol. 82 (25-26) , 1288-1292
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Correlation between CpG methylation profiles and hormone receptor status in breast cancersBreast Cancer Research, 2007
- Promoter hypermethylation of TMS1, BRCA1, ERα and PRB in serum and tumor DNA of invasive ductal breast carcinoma patientsLife Sciences, 2007
- Frequent loss of Dab2 protein and infrequent promoter hypermethylation in breast cancerBreast Cancer Research and Treatment, 2006
- Detection of RASSF1A and RAR? Hypermethylation in Serum DNA from Breast Cancer PatientsEpigenetics, 2006
- BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profilesBreast Cancer Research and Treatment, 2005
- Circulating Tumor-Specific DNA: A Marker for Monitoring Efficacy of Adjuvant Therapy in Cancer PatientsCancer Research, 2005
- Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patientsOncogene, 2003
- DNA methylation and breast carcinogenesisOncogene, 2002
- BRCA1 Expression Status in Relation to DNA Methylation of the BRCA1 Promoter Region in Sporadic Breast CancersJapanese Journal of Cancer Research, 2000
- Low oestrogen receptor α expression in normal breast tissue underlies low breast cancer incidence in JapanThe Lancet, 1999